Ian Morrissey

Ian brings over 30 years of expertise in antimicrobial research and drug development. His extensive career spans renowned institutions and companies, including the School of Pharmacy (London), Daiichi Pharmaceutical (Tokyo), University of Hertfordshire, GR Micro Ltd., Quotient Bioresearch, and IHMA Europe, where he has made significant contributions to the advancement of new antimicrobial agents and resistance management.

Throughout his career, he has led preclinical studies, resistance surveillance, and antimicrobial susceptibility testing for both small molecules and biologicals. His work includes research and development for a diverse portfolio of therapeutics, such as ceftaroline, ciprofloxacin, daptomycin, moxifloxacin, and tigecycline, among many others.

With academic qualifications in Applied Biology (BSc), Microbiology (PhD), and an Executive MBA, Ian has held leadership roles including CEO of GR Micro Ltd., overseeing its acquisition by Quotient Bioresearch. A committed member of the global scientific community, he has served on the British Society for Antimicrobial Chemotherapy Council and contributed to the Clinical Laboratory Standards Institute and the Global Antibiotic Research & Development Partnership (GARDP). He is also the Section Editor for the Journal of Global Antimicrobial Resistance.